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Abstract
Microglial activation plays an important role in neuroinflammation, which contributes to neuronal damage, and
inhibition of microglial activation may have therapeutic benefits that could alleviate the progression of
neurodegeneration. Recent studies have indicated that the antimalarial agent artemisinin has the ability to inhibit
NF-kB activation. In this study, the inhibitory effects of artemisinin on the production of proinflammatory mediators
were investigated in lipopolysaccharide (LPS)-stimulated primary microglia. Our results show that artemisinin
significantly inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), monocyte
chemotactic protein-1 (MCP-1) and nitric oxide (NO). Artemisinin significantly decreased both the mRNA and the
protein levels of these pro-inflammatory cytokines and inducible nitric oxide synthase (iNOS) and increased the protein
levels of IkB-a, which forms a cytoplasmic inactive complex with the p65-p50 heterodimeric complex. Artemisinin
treatment significantly inhibited basal and LPS-induced migration of BV-2 microglia. Electrophoretic mobility shift
assays revealed increased NF-kB binding activity in LPS-stimulated primary microglia, and this increase could be
prevented by artemisinin. The inhibitory effects of artemisinin on LPS-stimulated microglia were blocked after IkB-a was
silenced with IkB-a siRNA. Our results suggest that artemisinin is able to inhibit neuroinflammation by interfering with
NF-kB signaling. The data provide direct evidence of the potential application of artemisinin for the treatment of
neuroinflammatory diseases.
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Introduction
Microglia, which are the resident macrophages of the central
nervous system (CNS), are recognized as the primary component
of the brain immune system [1]. They are activated during
neuropathological conditions to restore CNS homeostasis [2].
Once activated, microglia undergo morphological changes,
proliferate and upregulate surface molecules [3]. Activated
microglia can promote neuronal injury through the release of
proinflammatory and cytotoxic factors, including tumor necrosis
factor (TNF)-a, interleukin (IL)-1b, IL-6, NO and reactive oxygen
species (ROS) [4]. Studies have demonstrated that the inhibition of
pro-inflammatory mediators in microglia can attenuate the
severity of Alzheimer’s disease (AD), Parkinson’s disease (PD),
trauma, multiple sclerosis (MS) and cerebral ischemia [5–9]. Thus,
anti-inflammatory treatment via inhibition of microglial activation
is regarded as a promising strategy for the prevention of
neurodegenerative diseases [10].
Artemisinin (qinghaosu) is the active component of Artemisia
annua L. and is approved worldwide for the treatment and
prevention of malaria [11]. In addition to its antimalarial
properties, artemisinin and its derivatives have been demon-
strated to affect other cellular biochemical processes [12,13],
such as proliferation, angiogenesis, apoptosis and oxidative
stress. Recently, artemisinin has been shown to exert an
inhibitory effect on inducible nitric oxide synthase (iNOS)
synthesis and NF-kB activation in human astrocytoma T67 cells
[14]. A derivative of artemisinin, SM933, has been found to
inhibit the activity of NF-kB by preventing its degradation via
upregulation of its inhibitory protein kappa B alpha (IkB-a)i n
MOG-reactive splenocytes [15]. Taken together, these studies
support the conclusion that artemisinin may play a role in
immune regulation and act to reduce inflammation. The anti-
inflammatory effects of artemisinin on microglial activation,
however, are unknown. In the present study, we investigated the
effects of artemisinin on lipopolysaccharide (LPS)-stimulated
pro-inflammatory responses in microglia and the signaling
mechanism by which artemisinin modulates the pro-inflamma-
tory response.
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Artemisinin is not toxic to primary rat microglia in the
culture conditions used
The cytotoxic effects of artemisinin were evaluated with the
MTT assay by measuring the viability of primary rat microglia
that were incubated with artemisinin (2.5, 5, 10, or 20 mM) for 1 h
in the presence or absence of LPS (1 mg/ml). We also examined
the viability of primary rat microglia treated with 10 mM
artemisinin for 6, 12, or 48 h in the presence or absence of LPS
(1 mg/ml). Interestingly, no significant differences in cell viability
were found between normal primary rat microglia and microglia
treated with 10 mM artemisinin for 48 h (Fig. 1), which indicates
that the inhibitory effect that we observed was not due to
cytotoxicity.
Artemisinin inhibits NO and iNOS production in LPS-
stimulated primary rat microglia
To investigate the effects of artemisinin on NO production in
LPS-stimulated primary rat microglia, cells were treated with LPS
alone or with various concentrations of artemisinin for 24 h. As
shown in Fig. 2A, LPS alone markedly induced NO production
compared with the control group (P,0.01); however, artemisinin
significantly reduced LPS-induced NO production in a dose-
dependent manner. Pretreatment of microglia with 2.5, 5, 10, or
20 mM artemisinin for 1 h prior to LPS stimulation decreased NO
production to 70.063.6%, 49.764.0%, 34.762.5%, and
37.064.6% (P,0.05 vs. the LPS group), respectively, and the
maximal inhibitory efficacy occurred at 10 mM( P .0.05 vs. the
20 mM group). The effect of artemisinin on iNOS mRNA
expression was measured using RT-PCR analysis. Although the
iNOS mRNA was barely detected in unstimulated primary rat
microglia, it was expressed at high levels following stimulation with
1 mg/mL LPS for 3 h. Pretreatment with artemisinin inhibited this
LPS-stimulated iNOS mRNA production in a dose-dependent
manner (Fig. 2B). The protein levels of iNOS that were detected
by western blotting were also repressed by artemisinin (Fig. 2C).
These results show that artemisinin inhibited NO production
through the downregulation of iNOS mRNA and protein
expression in LPS-stimulated primary microglia.
Artemisinin inhibits the migration of microglia
In order to measure microglial cell motility and to study the
effects of artemisinin, we performed transwell migration assays.
BV-2 cells (a mouse microglial cell line) were added to the upper
well, and LPS, artemisinin, LPS + artemisinin, or DMSO as
solvent control were added to the lower chamber medium. The
migratory capacity of BV-2 cells was not changed by the
activation agent LPS alone (Fig. 3). In both, the resting and the
activated microglial phenotype, artemisinin caused a significant
attenuation of microglial migration (Fig. 3). These results
indicate that artemisinin has an inhibitory effect on microglial
motility.
Artemisinin inhibits the expression of cytokines in LPS-
stimulated primary rat microglia
To elucidate the potential effects of artemisinin on pro-
inflammatory cytokine production (e.g., TNF-a, MCP-1 and IL-
6), primary rat microglia were incubated with artemisinin (2.5, 5.0,
10, and 20.0 mM) in the presence or absence of LPS (1 mg/ml).
RT-PCR analysis was used to examine the cytokine mRNA
expression levels, and the expression levels of TNF-a, MCP-1 and
IL-6 were significantly up-regulated after treatment with LPS
(1 mg/ml). Interestingly, the LPS-stimulated mRNA levels of the
pro-inflammatory cytokines TNF-a, MCP-1 and IL-6 were
reduced by artemisinin (Fig. 4A). Moreover, the protein levels of
TNF-a, MCP-1 and IL-6 in the LPS-stimulated primary rat
microglia were significantly reduced dose responsively by artemi-
sinin treatment (Fig. 4B). These suggested that artemisinin
negatively regulates the expression of TNF-a, MCP-1 and IL-6
in LPS-stimulated primary microglia.
Artemisinin inhibits LPS-induced NF-kB activation in
primary microglia
Previous studies have shown that LPS increases NF-kB subunit
activation (via phosphorylation, ubiquitination, degradation and
translocation of p65 and IkB-a) and regulates the expression of
iNOS and pro-inflammatory cytokines [16–18]. Activation of
NF-kB has been reported to be inhibited by artemisinin [14,19].
We performed EMSA (electrophoretic mobility shift assay) studies
to investigate whether artemisinin inhibited NF-kB activation in
LPS-stimulated primary microglia. Interestingly, artemisinin
abolished the increased DNA binding activity of NF-kBt h a t
was observed in primary microglia stimulated with LPS (Fig. 5).
These data demonstrate that artemisinin inhibits NF-kB
activation in LPS-stimulated primary microglia and that this
mechanism may contribute to the anti-inflammatory effect of
artemisinin.
Figure 1. Effect of artemisinin and LPS on primary rat microglia viability. Viability in artemisinin-treated cells was evaluated using the MTT
assay. Cells were incubated with artemisinin (2.5 to 20 mM) and LPS (1 mg/ml) for 1 h and with 10 mM artemisinin and 1 mg/ml LPS for 6 to 48 h. The
results are displayed as the percentages of the control samples. The data are presented as the means 6 S.E.M. (n=5) for three independent
experiments.
doi:10.1371/journal.pone.0035125.g001
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35125Artemisinin treatment increases the IkB-a level in primary
microglia stimulated with LPS
Inhibition of NF-kB signaling may occur through a variety of
mechanisms, one of which may involve the enhanced expression of
IkB-a, which forms an inactive cytoplasmic complex with the p65-
p50 heterodimeric complex. We determined the protein levels of
IkB-a by western blot analysis using specific anti-IkB-a and anti-
phosphorylated IkB-a antibodies. Interestingly, the addition of
artemisinin to primary microglia exposed to LPS resulted in an
increase in the level of IkB-a. Because activation of NF-kB
requires IkB-a degradation, we assessed whether artemisinin
affected the protein level of phosphorylated IkB-a. Our data show
that the protein level of IkB-a was reduced (Fig. 6B and C), but
this reduction was not observed when cells were co-incubated with
artemisinin. In addition, we compared artemisinin to PDTC,
which is a specific inhibitor of NF-kB, to investigate whether
artemisinin was inhibiting NF-kB activity. Figure 6 shows
arteminisin (10 mM) alone had no effect on the IkB-a degradation
and phosphorylation; however, it prevented LPS-induced degra-
dation and phosphorylation of IkB-a. Artemisinin inhibited NF-
kB activity to a similar degree as PDTC (300 mM) (Fig. 6A–C).
These results indicate that artemisinin inhibited LPS-induced NF-
kB activation by preventing IkB-a degradation and phosphory-
lation in primary microglia.
The anti-inflammatory effects of artemisinin in LPS-
stimulated primary microglia were blocked by siRNA
To determine whether the anti-inflammatory effects of
artemisinin are due to the inhibition of NF-kB activation by the
enhanced expression of IkB-a, we also examined the changes in
cytokine expression levels in LPS-stimulated primary rat microglia
after IkB-a siRNA transfection. We observed that silencing IkB-a
with siRNA increased the TNF-a, MCP-1 and IL-6 mRNA
expression levels in LPS-stimulated primary microglia. Interest-
ingly, artemisinin inhibited the LPS-induced increase in TNF-a,
MCP-1 and IL-6 mRNA expression, but this effect was
significantly reduced after IkB-a siRNA transfection (Fig. 7A–D).
Discussion
To the best of our knowledge, the present study was the first to
demonstrate that artemisinin inhibits the inflammatory activation
of microglia. Artemisinin significantly reduced inflammatory
mediators, such as TNF-a, MCP-1, IL-6 and NO production, in
LPS-activated primary microglia in vitro, and the RT-PCR analysis
showed that artemisinin markedly suppressed TNF-a, MCP-1, IL-
6 and iNOS gene expression. The anti-inflammatory properties of
artemisinin are mediated by the interruption of NF-kB signaling
Figure 2. Artemisinin inhibition of LPS-induced nitrite production in primary rat microglia. Cells were pretreated with the indicated
concentrations of artemisinin for 1 h before incubating with LPS (1 mg/ml) for 3 h. The culture medium was collected to assay the nitrite levels (A).
The cells were lysed, and the lysates were prepared for the detection of mRNA levels (B) and western blot analysis with an anti-iNOS antibody (C). The
data are presented as the means 6 S.E.M. (n=5) for three independent experiments. *P,0.05 vs. LPS alone.
doi:10.1371/journal.pone.0035125.g002
Figure 3. Artemisinin inhibition of microglial motility. Transwell
chamber migration of BV-2 microglial cells treated with solvent control,
10 mM artemisinin, 100 ng/ml LPS, or 10 mM artemisinin + 100 ng/ml
LPS for 24 hours. The absolute number of migrating cells was counted
in the lower chamber and mean values 6 SEM are displayed. * P#0.05
for artemisinin vs. control, and # P#0.05 for artemisinin + LPS vs. LPS,
Student’s t test.
doi:10.1371/journal.pone.0035125.g003
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35125pathways in microglia. Artemisinin and its derivatives are
commonly used in the treatment of patients with severe and
chloroquine-resistant malaria [20]. To the best of our knowledge,
however, there is no evidence regarding the effects of artemisinin
on the inflammatory activation of microglia. Our study found that
treatment with 20 mM artemisinin for 48 h did not affect cell
viability, which indicates that the primary effects of artemisinin
actions are anti-inflammatory rather than cytotoxic.
Microglial cells are brain macrophages that serve specific
functions in the defense of the CNS against microorganisms, the
removal of tissue debris in neurodegenerative diseases or during
normal development, and in autoimmune inflammatory disorders
of the brain [3]. Microglia activation plays a crucial role in the
initiation and progression of brain inflammation, which is thought
to aggravate pathological conditions in the CNS by releasing
various proinflammatory cytokines and free radicals [21–23].
These factors are believed to contribute to microglia-mediated
neurodegeneration [22,24,25]. Several immune stimulants, such as
IFN-c, LPS and TNF-a, are known to activate microglial cells
[26–28]. LPS, which is a natural Toll-like receptor 4 (TLR4)
ligand, has been the most extensively utilized microglial activator
for the induction of an inflammatory response. Thus, the present
study used LPS as an experimental model to activate microglia.
Figure 4. The effects of artemisinin on LPS-induced TNF-a, MCP-1 and IL-6 expression in primary rat microglia. Cells were treated with
the indicated doses of artemisinin for 1 h before LPS treatment (1 mg/ml). After incubation for 3 h, the mRNA levels of TNF-a, MCP-1 and IL-6 were
determined by RT-PCR (A) and the protein levels were analyzed by western blot (B). The data are presented as the means 6 S.E.M. (n=5) for three
independent experiments. *P,0.05 vs. LPS alone.
doi:10.1371/journal.pone.0035125.g004
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35125Activated microglia produce a wide range of proinflammatory
mediators, including TNF-a, IL-6, IL-1b, ROS, and NO. NF-kB
is an essential and ubiquitous transcription factor for the
expression of many inflammation-related genes, including TNF-
a, IL-6, IL-1b and iNOS. LPS has also been reported to activate
NF-kB in microglia [29,30], and NF-kB activation and IkB-a
degradation are known to be involved in LPS/IFNc-induced
iNOS expression [16]. Recent studies have indicated that
artemisinin and its derivatives may exert anti-inflammatory and
immunoregulatory effects by inhibiting NF-kB activation [19]. In
human rheumatoid arthritis fibroblast-like synoviocytes, artesu-
nate, an artemisinin derivative, has the ability to inhibit TNF-a-
induced production of proinflammatory cytokines via inhibition of
NF-kB and PI3 kinase/Akt signal pathway [19]. Both in THP-1
and in RAW 264.7 macrophages, artemisinin and its derivatives
inhibited pro-inflammatory cytokine production by NF-kB
pathway [31,32]. Due to its anti-inflammatory properties, the role
of artemisinin in LPS-activated microglia was investigated in this
study. Our results showed that LPS mediated an intense
proinflammatory response in primary rat microglia, which was
consistent with numerous reports. The production of NO free
radicals and pro-inflammatory cytokines, including TNF-a, IL-6,
and MCP-1, were increased in the LPS-stimulated microglia after
24 h. Interestingly, concentrations of artemisinin ranging from 1
to 20 mM significantly suppressed microglial activation and the
pro-inflammatory response induced by LPS in a concentration-
dependent manner without causing cytotoxicity. Artemisinin
inhibited the activity of NF-kB and its capacity to bind DNA in
primary microglia subjected to LPS. NF-kB is a critical signal
transcription factor for regulating immune and inflammatory
responses. Importantly, the activity of NF-kB is regulated by its
subcellular localization, and NF-kB is retained in the cytosol when
bound to inhibitors of kB (i.e., IkB). In resting cells, NF-kBi s
sequestered in the cytoplasm by the IkB family, including IkB-a
and IkB-b. Activation of the IkB proteins, which can be induced
by a variety of stimuli, such as pro-inflammatory cytokines, results
in the phosphorylation of the IkB proteins by a complex of IkB
kinases (IKK). After phosphorylation, IkB proteins are ubiquiti-
nated and rapidly degraded by the proteasome, which allows NF-
kB to be released from IkB and translocate to the nucleus where it
Figure 5. Artemisinin inhibits LPS-induced NF-kB activation in
primary microglia. The DNA binding activity of NF-kB was evaluated
by EMSA in cells pretreated with 10 mM artemisinin for 12, 24, or 48 h
prior to a 3 h incubation with LPS (1 mg/ml). The data represent the
means 6 S.E.M of three independent experiments. * P,0.05 vs. the
artemisinin group.
doi:10.1371/journal.pone.0035125.g005
Figure 6. The effects of artemisinin on LPS-induced degrada-
tion and phosphorylation of IkB-a. (A) After treatment with
artemisinin (10 mM) or PDTC (a specific inhibitor of NF-kB, 300 mM)
for 24 h, primary rat microglia were stimulated with LPS (1 mg/ml) for
30 min. The LPS-induced degradation and phosphorylation of IkB-a
were analyzed by western blot analysis. (B and C) Data are presented as
the means 6 S.E.M. from five separate experiments. *P,0.05 vs.
untreated control and **P,0.05 vs. treatment with LPS alone.
doi:10.1371/journal.pone.0035125.g006
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promoter elements [33,34]. In the present study, we demonstrated
that artemisinin increased the expression of IkB-a. The effect of
artemisinin on activated microglia was blocked by IkB-a siRNA.
Therefore, increased expression of IkB-a likely resulted in
persistent binding to NF-kB, which blocked NF-kB translocation
to the nucleus and prevented its activity.
In conclusion, the present study demonstrated that artemisinin
inhibited LPS-induced production of inflammatory mediators,
such as TNF-a, IL-6, MCP-1, and NO, in primary microglia. The
anti-inflammatory properties of artemisinin are mediated by its
effects on the NF-kB signaling pathway in LPS-stimulated
microglia. The data from the present study suggest that
artemisinin may be developed as a therapeutic agent for the




Griess reagent, LPS, N,N-dimethyl sulfoxide (DMSO) and
pyrrolidinedithiocarbamate (PDTC) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s
medium (DMEM/F12), fetal bovine serum (FBS), antibiotics,
trypsin-EDTA, phosphate-buffered saline (PBS) and other prod-
ucts for cell culture were purchased from Invitrogen (Carlsbad,
CA, USA). Antibodies against IkB-a and phosphorylated-IkB-a
(Ser32) were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). Mouse anti-rat OX-42 (CD11b) antibody
was obtained from AbD Serotec (Oxford, Canterbury, UK).
Artemisinin was purchased from Guilin Pharmaceutical Factory
(Guilin, Guangxi, P. R. China) and was dissolved in DMSO (final
concentration ,0.1% v/v).
Primary microglial cell culture
Sprague-Dawley rats were obtained from the Experimental
Animal Center of Sun Yat-sen University (Guangzhou, China).
Experiments were carried out according to the National Institutes
of Health Guide for Care and Use of Laboratory Animals and
were approved by the Bioethics Committee of Sun Yat-sen
University. Primary microglia were cultured from postnatal day 1
Sprague-Dawley rats as previously described [35]. Briefly, cerebral
cortical fragments were dissociated by soft trituration in ice-cold
DMEM containing 10% FBS, 2 mM glutamine, 100 IU/mL
penicillin, and 100 mg/mL streptomycin. The cortical fragments
were resuspended in culture medium and made into a single cell
suspension by repeated pipetting. Single cells were plated on 100-
mm culture dishes and incubated at 37uC in humidified 5% CO2/
95% air for 2 weeks. The microglia were detached from the flasks
by mild shaking and applied to a nylon mesh to remove astrocytes
and cell clumps. Isolated microglia were plated on 24-well plates at
a density of 2610
5 cells/well, and cultures with .90% purity of
Figure 7. LPS-induced TNF-a, MCP-1 and IL-6 mRNA expression in primary rat microglia after treatment with IkB-a siRNA. IkB-a
protein expression in primary rat microglia transfected with IkB-a siRNA for 48 h (A). The effects of artemisinin on LPS-induced TNF-a (B), MCP-1 (C)
and IL-6 (D) mRNA expression in cultured cells after incubation with IkB-a siRNA for 48 h. The data are presented as the means6S.E.M. from five
separate experiments. *P,0.05 vs. control,
#P,0.05 vs. treatment with LPS alone, and
$P,0.05 vs. treatment with LPS and artemisinin.
doi:10.1371/journal.pone.0035125.g007
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The cells were cultured for 2 days before drug treatment.
BV-2 microglial cell culture
BV-2 cells were maintained in DMEM with 10% fetal bovine
serum FBS in a 5% CO2 incubator. Plated cells were grown in
DMEM with 10% FBS overnight. BV-2 cells were stimulated with
100 ng/ml LPS, 10 mM of artemisinin, or DMSO as control for
6 h. These stimulation conditions were adapted from previously
published experiments [36].
Cell viability assay
Cell viability was determined by the tetrazolium salt 3-[4,5-
dimethylthiazol-2-yl] -2,5-diphenyltetrazolium bromide (MTT,
Sigma-Aldrich) assay. Briefly, cells were seeded and treated with
LPS (1 mg/mL) and various concentrations of artemisinin (ranging
from 1 to 20 mM) for 1 h. The cells were also treated with 10 mM
artemisinin and 1 mg/ml LPS for 6 to 48 h. After incubation for
the indicated time, 0.5 mg/ml MTT was added to each well. The
dark blue formazan crystals that were produced were dissolved in
acidified isopropanol, and formazan quantification was performed
at a test wavelength of 570 nm and a reference wavelength of
620 nm. Each experiment was performed in triplicate.
siRNA transfection
The siRNA sequences that were used to silence IkB-a
(GenBank NM_001105720) were designed and synthesized by
Guangzhou Ribobio (Guangzhou, China): sense, 59-CCAUG-
GAAGUGAUUGGUCAGGUGAA-39; antisense, 59-UUCAC-
CUGACCAAUCACUUCCAUGG-39. For nonsense control
siRNA, we used irrelevant siRNA with random nucleotides that
had no known specificity: sense, 59-CCAAAGGUGUUAUGG-
GACUGUGGAA-39; antisense, 59-UUCCACAGUCCCAUAA-
CACCUUUGG-39. Microglia (1610
6) were plated in a 6-well
plate, incubated for 48 h, and transfected with an IkB-a-specific
siRNA duplex (50 nM final concentration) or the nonsense control
siRNA (50 nM) using the Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. The
transfected cells were stimulated with LPS (1 mg/ml) or artemi-
sinin for 48 h.
Nitrite assay
The production of NO was assayed by measuring the levels of
nitrite, a stable NO metabolite, in the culture medium.
Accumulation of nitrite in the medium was determined by a
colorimetric assay with the Griess reagent. The supernatant was
collected and mixed with an equal volume of Griess reagent (0.1%
N-1-naphthylethylenediamine dihydrochloride and 1% sulphanil-
amide in 5% phosphoric acid) in a 96-well plate and incubated for
10 min at room temperature in the dark. Nitrite concentrations
were determined using standard solutions of sodium nitrite
prepared in cell culture medium. Absorbance was measured at
550 nm in a microplate reader.
Transwell migration assay
Costar Transwell polycarbonate filters (8-mm pore size) were
used in a migration assay to examine the ability of microglia
migration. 1610
6 BV-2 cells in 1.5 ml serum-free medium were
added to the upper well, and 2.6 ml serum-free medium was
added to the lower chamber. 100 ng/ml LPS, 10 mm artimisinin,
100 ng/ml LPS + 10 mm artimisinin, or DMSO as solvent control
were added to the lower chamber medium. At the end of a 24 h
incubation period, cells that had migrated to the lower surface
were quantified by counting the migrated cells on the lower
surface of the membrane using microscopy.
Western blot and quantitative real-time RT-PCR
Cells were pretreated with artemisinin prior to incubation with
LPS. The cells were rinsed twice with ice-cold PBS and incubated
in 0.5 ml of ice-cold lysis buffer for 20 min on ice. After the
incubation, the cells were scraped and centrifuged. Cells were
lysed in RIPA lysis buffer, and the protein concentrations were
determined using the BCA protein assay (Pierce, Rockford, IL,
USA). Equal amounts of protein were solubilized in Laemmli
buffer, boiled for 5 min, separated by SDS-polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes.
Primary antibodies for IkB-a and phosphorylated-IkB-a (Ser32)
were diluted 1:500 in Tris-buffered saline with Tween (TBS-T)
containing 5% nonfat milk, and the membranes were probed with
the antibodies at 4uC overnight. After incubation with the primary
antibody, the membranes were incubated with the appropriate
secondary antibodies for 1 h at room temperature. Immunoreac-
tive bands were visualized by an enhanced chemiluminescence
(ECL, Amersham Pharmacia Biotech, Piscataway, NJ, USA)
reaction.
For real-time reverse transcription PCR, total RNA was
extracted from induced cell cultures using TRIzol (Invitrogen),
and cDNA was synthesized using primers with the Advantage RT-
for-PCR kit (BD Biosciences). We quantified the PCR amplifica-
tions using SYBR Green PCR Master Mix (Applied Biosystems),
and the results were normalized to GAPDH gene expression. All
of the experiments were performed in triplicate and repeated at
least three times.
Electrophoretic mobility shift assay
To examine the DNA binding activity of NF-kB, electropho-
retic mobility shift assays (EMSAs) were performed according to
the manufacturer’s instructions (Gel Shift Assay System E3300,
Promega, Madison, WI). Nuclear proteins were isolated as
previously described [37], and protein concentrations were
determined using the BCA protein assay with bovine serum
albumin (BSA) as a standard.
Statistical analysis
The results are presented as the means 6 S.E.M, and one-way
analysis of variance (ANOVA) was used to test the significance
between groups. The Student’s t test was used for the comparison
of experimental groups in cell migration assays. Differences were
considered significant at P,0.05.
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